This trial is active, not recruiting.

Condition obesity
Sponsor Vanderbilt University
Start date March 2011
End date November 2013
Trial size 24 participants
Trial identifier NCT00993460, IRB #091145


Research has shown that fat stored within muscles affects the muscle's sensitivity to insulin and ability to handle blood glucose. The purpose of this study is to examine the effects of weight loss surgery-induced caloric restriction on the accumulation and types of fats within skeletal muscle, as well as the effects of such caloric restriction on insulin sensitivity and inflammatory responses in skeletal muscle. The investigator proposes that caloric restriction will result in decreases in diacylglycerols enriched with saturated fat and increases in diacylglycerols enriched with monounsaturated fats.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Female subjects, ages 21-65 yrs, with BMI of 21-27 kg/m2 with normal glucose tolerance.
Female subjects ages 21-65 with insulin resistance and scheduled for Roux-en-Y gastric bypass at Vanderbilt University Medical Center will be studied before and 4-6 weeks after surgery.

Primary Outcomes

UPLC-ESI MS/MS profiling of lipd extracts from muscle biopsies to evaluate effects of gastric bypass induced-caloric restriction on diacylglycerol molecular species accumulation.
time frame: 1 year

Secondary Outcomes

To evaluate the effects of gastric bypass induced-caloric restriction on skeletal muscle insulin action via a hyperinsulinemic-euglycemic clamp and profiling markers of insulin signaling.
time frame: 1 year
To evaluate the effects of gastric bypass induced-caloric restriction on lipid-mediated inflammatory responses by profiling cytokines and free fatty acids in blood and inflammation markers in skeletal muscle biopsies.
time frame: 1 year

Eligibility Criteria

Female participants from 21 years up to 65 years old.

Inclusion Criteria: - For Normal Weight Subjects: - Age 21-65 years - BMI of 21 to 27 kg/m2 - Normal glucose tolerance as determined by OGTT on day of screening - No family history of diabetes - For Morbidly Obese Subjects: - Age 21-65 years - BMI of 30 to 65 kg/m2 - Scheduled for Roux-en-Y gastric bypass at Vanderbilt Medical Center - Insulin resistant as determined by OGTT on day of screening Exclusion Criteria (for all subjects): - Clinically significant heart disease - Clinically significant hepatic or renal disease - Pregnancy - Breastfeeding - Any abnormality that would preclude safe completion of study - Use of statins - Use of thiazide or furosemide diuretics, beta blockers, or other chronic medications with known adverse effects on glucose tolerance levels unless subject has been on stable dose of such medications for the past 3 months before entering the study

Additional Information

Official title Diacylglycerols and Insulin Action in Skeletal Muscle Upon Caloric Restriction
Principal investigator Charles R Flynn, PhD
Description We hypothesize that in a setting of surgically-induced weight loss decrements in select DAGs result in improved glucose utilization, altered insulin signaling and decreased inflammatory responses. We propose to examine the impact of molecular DAG species accumulation on glucose utilization, insulin signaling and inflammation in skeletal muscle from morbidly obese subjects before/after 10% weight loss facilitated by Roux-en-Y Gastric Bypass (RYGB). We will compare these results to those from a control, normal weight cohort The detected differences in DAG molecular species, insulin action, inflammatory responses between normal and obese subjects (before/after weight loss) will emphasize pathways coordinately altered as a consequence of adiposity and RYGB surgery. The primary endpoints for this study will be: Insulin sensitivity (glucose Rd, insulin levels, DAG mass, DAG species amounts).Secondary endpoints will be: FFA levels, inflammatory cytokine production, and insulin signaling in skeletal muscle.
Trial information was received from ClinicalTrials.gov and was last updated in February 2017.
Information provided to ClinicalTrials.gov by Vanderbilt University Medical Center.